Eissa H., Thakar M.S., Shah A.J., Buckley R. H., Logan B., Griffith L.M., Dong H., O’Reilly R.J., Kapoor N., Satter L.F., Chandra S., Bleesing J.J., Kapadia M., Parrott R.E., Chandrakasan S., Bednarski J.J. II, Jyonouchi S., Madden L.M., Rayes A., Ebens C., Teira P., Saldaña B.J.D., Burroughs L.M., Prockop S.E., Williams O., Chellapandian D., Gillio A.P., Goldman F., Malech H.L., DeSantes K., Cuvelier G.D.E., Rozmus J., Quinones R., Yu L.C., Broglie L., Aquino V., Shereck E., Moore T.B., Martinez C., Lugt M.T.V., Leiding J.W., Torgerson T.R., Pai S-Y., Pulsipher M.A., Notarangelo L.D., Puck J., Dvorak C.C., Haddad E., Cowan M., and Heimall J. (2022). 437 - A primary immune deficiency treatment consortium (PIDTC) study of chronic and late onset medical complications after initial hematopoietic cell transplantation (HCT) for severe combined immunodeficiency disease (SCID). Trans. Cell. Therapy, 28(3): S339–S340.